Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 11/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 8/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13342425 | 0.85 | MAP2K1 (0.60) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL12917636 | 0.81 | MAP2K1 (1.00) | MAP2K1RAF1CYP2C9CYP3A4BRAF | |
| SCHEMBL970190 | 0.80 | MAP2K1 (0.70) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL971526 | 0.79 | MAP2K1 (0.59) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL31980592 | 0.79 | MAP2K1 (0.70) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL960703 | 0.79 | MAP2K1 (0.70) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL12694056 | 0.78 | MAP2K1 (0.69) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL959667 | 0.76 | MAP2K1 (0.70) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL960504 | 0.75 | MAP2K1 (0.65) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL963772 | 0.75 | MAP2K1 (0.64) | MAP2K1ALDH1A1KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7026491-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2002008217-A2 | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3709/4885ALDH1A1 1457/4885KDM4E 4511/4885 |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885ALDH1A1 1402/4885KDM4E 4508/4885 |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAP2K1 3808/4885ALDH1A1 1402/4885KDM4E 4508/4885 |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAP2K1 3811/4885ALDH1A1 1823/4885KDM4E 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.